Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S L Chan

Showing results (381-390 of 385) with videos related to

Pageof 39
Sort By:
You have reached the last page of results.This site can display upto 385 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2024
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinomaB Sangro, S L Chan, R K Kelley, et al.
Cell|September 29, 2020
Translocation of Viable Gut Microbiota to Mesenteric Adipose Drives Formation of Creeping Fat in HumansConnie W Y Ha, Anthony Martin, Gregory D Sepich-Poore, et al.
Respirology (Carlton, Vic.)|March 25, 2017
Australian and New Zealand Pulmonary Rehabilitation GuidelinesJennifer A Alison, Zoe J McKeough, Kylie Johnston, et al.
ESMO Open|July 6, 2026
Cisplatin-gemcitabine-durvalumab reintroduction in advanced biliary tract cancer: a multinational real-world analysisS Camera, A Vogel, M Rimini, et al.
ESMO Gastrointestinal Oncology|May 22, 2026
Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort studyH Vandeputte, A Casadei-Gardini, F Peeters, et al.
Pageof 39

Showing results (381-390 of 385) with videos related to

Sort By:
Pageof 39
You have reached the last page of results.This site can display upto 385 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2024
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinomaB Sangro, S L Chan, R K Kelley, et al.
Cell|September 29, 2020
Translocation of Viable Gut Microbiota to Mesenteric Adipose Drives Formation of Creeping Fat in HumansConnie W Y Ha, Anthony Martin, Gregory D Sepich-Poore, et al.
Respirology (Carlton, Vic.)|March 25, 2017
Australian and New Zealand Pulmonary Rehabilitation GuidelinesJennifer A Alison, Zoe J McKeough, Kylie Johnston, et al.
ESMO Open|July 6, 2026
Cisplatin-gemcitabine-durvalumab reintroduction in advanced biliary tract cancer: a multinational real-world analysisS Camera, A Vogel, M Rimini, et al.
ESMO Gastrointestinal Oncology|May 22, 2026
Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort studyH Vandeputte, A Casadei-Gardini, F Peeters, et al.
Pageof 39